The groundbreaking success of Sildenafil undeniably transformed the pharmaceutical landscape, but investing in companies strongly reliant on off-patent versions presents a uncertain picture. Although early returns were impressive, the cessation of patents and the appearance of less expensive alternatives have weakened sales. Consequently, a thor… Read More